Azenta, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZTA research report →
Range $52 – $52
Price Chart
About the company
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets.
- CEO
- Martin D. Madaus
- IPO
- 1995
- Employees
- 2,900
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on AZTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.87B
- P/E
- -12.38
- Fwd P/E
- 78.60
- PEG
- 0.07
- P/S
- 3.01
- P/B
- 1.39
- EV/EBITDA
- -18.30
- Div Yield
- 0.00%
- Gross Margin
- 44.23%
- Op Margin
- -27.72%
- Net Margin
- -26.86%
- ROE
- -10.81%
- ROIC
- -11.68%
Latest fiscal year · YoY change
- Revenue
- $621.70M+4.7%
- Gross Profit
- $274.96M+1.7%
- Op Income
- $-174,699,000
- Net Income
- $-166,985,000-199.5%
- EPS
- $-3.70-203.3%
- OCF Growth
- -20.3%
- FCF Growth
- -28.4%
- 52W High
- $50.06
- 52W Low
- $15.93
- 50D MA
- $37.84
- 200D MA
- $28.65
- Beta
- 1.47
- RSI (14)
- 56
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Azenta said fiscal 2026 ended with better second-half momentum, and it guided fiscal 2027 for 3% to 5% organic growth, 200 to 250 bps of adjusted EBITDA margin expansion, and stronger cash generation.· November 11, 2026
- Q4 revenue was $167 million, up 5% reported and 2% organically; full-year revenue was $622 million, up 5% reported and 2% organically.
- Q4 adjusted EBITDA was $19.4 million with an 11.6% margin; full-year adjusted EBITDA was $58.3 million with a 9.4% margin.
- Non-GAAP EPS was $0.28 in Q4 and $0.48 for the full year.
- Management said booking trends improved across the business, especially in Automated Stores and Multiomics, and cited stronger second-half execution.
- Fiscal 2027 guidance calls for $648 million to $660 million of revenue, about 3% to 5% organic growth, and roughly 100 bps of first-quarter EBITDA margin expansion.
- The company also highlighted restructuring actions expected to generate about $11 million of annualized savings, plus investments in Elegen and SynPlexity to expand gene synthesis.
Q4 revenue was $167 million, up 5% as reported and 2% organically. Full-year fiscal 2026 revenue was $622 million, up 5% as reported and 2% organically, and exceeded the high end of guidance. Q4 adjusted EBITDA was $19.4 million with an 11.6% margin; full-year adjusted EBITDA was $58.3 million with a 9.4% margin. Non-GAAP EPS was $0.28 in Q4 and $0.48 for the full year. Free cash flow was $12 million in Q4 and $27 million for the full year. The company ended the year with $506 million in cash, cash equivalents, restricted cash, and marketable securities, with no debt outstanding. For fiscal 2027, Azenta expects total reported revenue of approximately $648 million to $660 million, organic growth of approximately 3% to 5%, and adjusted EBITDA margin expansion of about 200 to 250 basis points. For Q1 fiscal 2027, it expects organic revenue growth of about 3% to 4% and adjusted EBITDA margin expansion of about 100 to 150 basis points versus Q1 fiscal 2026. Full-year free cash flow is expected to improve by approximately 25% versus fiscal 2026.
Martin Madaus framed fiscal 2026 as a year of stabilization and said the business improved meaningfully in the second half. He emphasized three priorities for fiscal 2027: profitable revenue growth, consistent execution, and targeted cost control, while noting that the company is now focused on turning the operating actions already taken into more predictable performance. His tone was confident but disciplined, repeatedly stressing that the company must now deliver on its commitments quarter by quarter.
Lawrence Lin focused on the financial mechanics behind the outlook. He pointed to gross margin improvement in Q4, with adjusted gross margin at 47.2%, and said fiscal 2027 margin expansion should come from gross margin, operating leverage, restructuring benefits, and productivity, partly offset by about 100 bps of dilution from Elegen and SynPlexity. He also noted $506 million of cash and marketable securities, no debt, $68 million of Q4 share repurchases, and expected $11 million of annualized savings from the October restructuring actions once substantially complete around the end of Q2 fiscal 2027.
Analysts focused heavily on Multiomics, especially North America stability, the impact of the Elegen and SynPlexity deals, and what those additions mean for growth, cost competitiveness, and margins. Management said the North America recovery reflected better execution, sales-force seasoning, and steadier market demand, while reiterating that the new gene synthesis capabilities address larger addressable markets and should be accretive over time. Questions also probed the company’s long-term plan and improved bookings in Automated Stores; management said bookings have improved because customer capital spending is loosening and that the business now has good visibility into 2027, though execution and project timing still matter.
The company is seeing better booking trends, stronger second-half execution, and double-digit growth in parts of Sample Repository Services, Consumables & Instruments, and gene synthesis. Management believes the restructuring, new product launches, and the Elegen/SynPlexity additions can support a more profitable and scalable growth profile in 2027 and beyond.
Automated Stores and Sanger sequencing remained clear drags in 2026, and management said Sanger will still be a headwind in 2027, though smaller than before. The new gene synthesis investments are still early-stage, carry about 100 bps of expected dilution in the 2027 outlook, and the company said free cash flow will be negative in Q1 because of integration, restructuring, and capital spending.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.2%
- Shares Outstanding
- 41.76M
- Float Shares
- 36.83M
of shares held by institutions
259 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AZTA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 15, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Oct 9, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Mar 19, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 14, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 13, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 3, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 15, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.02M | ▼ 511.69K |
| Politan Capital Management LP | 4.62M | 0 |
| Vanguard Group Inc | 4.54M | ▲ 99.59K |
| Vanguard Portfolio Management LLC | 2.43M | ▼ 60.53K |
| State Street Corp | 1.78M | ▼ 76.31K |
| Vanguard Capital Management LLC | 1.74M | ▼ 128.69K |
| Dimensional Fund Advisors LP | 1.20M | ▼ 33.74K |
| Morgan Stanley | 1.15M | ▼ 184.74K |
| D. E. Shaw & Co., Inc. | 1.13M | ▼ 209.80K |
| Geode Capital Management, LLC | 1.11M | ▲ 6.42K |
| Neuberger Berman Group LLC | 1.01M | ▼ 124.86K |
| Gw&K Investment Management, LLC | 992.62K | ▲ 4.19K |
Held by 201 ETFs
Biggest fund positions in AZTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Pirogova Olga | other | 13,412 |
| Nov 16, 26 | Pirogova Olga | other | 2,072 |
| Nov 16, 26 | Pirogova Olga | other | 5,009 |
| Nov 12, 26 | Pirogova Olga | other | 10,339 |
| Nov 12, 26 | Lin Lawrence Y. | other | 23,262 |
| Nov 16, 26 | Lin Lawrence Y. | other | 4,413 |
| Nov 12, 26 | Starr Ephraim | other | 21,711 |
| Nov 12, 26 | MARTIN WILLIAM E. III | other | 17,576 |
| Nov 12, 26 | Bello Erik J. | other | 5,815 |
| Oct 22, 26 | Madaus Martin D | other | 1,294 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZTA coverage
Recent articles, reports, and earnings notes.
No research on AZTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZTA report →Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
globenewswire.com · Nov 18
Azenta to Participate in the 9th Annual Evercore Healthcare Conference
prnewswire.com · Nov 17
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
newsfilecorp.com · Nov 16
Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
globenewswire.com · Nov 15
ROSEN, A LONGSTANDING LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
newsfilecorp.com · Nov 14
What Azenta (AZTA) Said on Its Q4 Earnings Call
defenseworld.net · Nov 14
Azenta, Inc. $AZTA Stock Sold by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 14
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
newsfilecorp.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.